Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. related to its proposed acquisition by XOMA Royalty Corporation, where stockholders will receive $1.95 in cash and one contingent value right for each share held, with the transaction expected to close in September 2025 [1]. Group 1 - HilleVax, Inc. is under investigation for potential securities law violations concerning its acquisition by XOMA Royalty Corporation [1]. - Stockholders of HilleVax will receive $1.95 in cash and one contingent value right for each share they hold as part of the acquisition deal [1]. - The acquisition transaction is anticipated to close in September 2025 [1]. Group 2 - Rowley Law PLLC represents shareholders in class actions and derivative lawsuits in complex corporate litigation [3]. - Additional information regarding the investigation can be obtained by contacting Rowley Law PLLC [2].

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton LLP is investigating agilon health, Inc. (NYSE: AGL) for potential securities law violations. Investors who have lost money in their agilon investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/agl. Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investor ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all individuals and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to participate in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Vestis Corporation provided overly positive statements while concealing material adverse facts about its business growth capabilities. Specifically, it was claimed that Vestis would struggle to execute strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year. The company reported a significant decline in stock price, dropping from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [3]. Class Action Details - The class period for the lawsuit is defined as May 2, 2024, to May 6, 2025. Shareholders are encouraged to register for participation in the class action, with a deadline set for August 8, 2025. Registration allows shareholders to receive updates on the case [3][4]. Law Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights against deceit and fraud, seeking recovery for those who suffered losses due to misleading statements that inflated stock prices [5].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities between November 7, 2024, and July 8, 2025 [1][2] Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2] Legal Allegations - The lawsuit alleges that RxSight failed to disclose: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3] 2. Overstated demand for RxSight's products [3] 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3] Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance [4] - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4]

NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=158122&from=4CLASS PERIO ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vestis Corporation (NYSE: VSTS). Shareholders who purchased shares of VSTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vestis-corporation-loss-submission-form/?id=157785&from=3 CLASS PERIOD: May 2, 20 ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157789&from=3 CLASS PERIOD: A ...

Company Overview - Barnes & Noble Education, Inc. operates and manages campus bookstores, e-commerce sites, and digital courseware platforms for colleges, universities, and K–12 institutions across the United States [3] Allegations and Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Barnes & Noble, stemming from allegations of providing potentially misleading business information to the investing public [1] - On July 18, 2025, Barnes & Noble announced a delay in filing its annual report for the fiscal year ended May 3, 2025, due to an ongoing internal investigation into its digital sales recording methods [4] - Initial findings from the investigation suggest that Barnes & Noble may have overstated its accounts receivable by up to $23 million and expects to disclose material weaknesses in its internal controls [4] Market Reaction - Following the announcement of the investigation and the delay in filing, Barnes & Noble's stock price fell by $2.36 per share, or 21.02%, closing at $8.87 per share on July 21, 2025 [5]

Core Viewpoint - DJS Law Group is investigating GeneDx Holdings Corp. for potential violations of securities laws, focusing on allegations of fraudulent activities and misleading statements made by the company [1][2]. Group 1: Investigation Details - The investigation is centered on whether GeneDx made false or misleading statements or failed to disclose material information relevant to investors [2]. - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at manipulating Medicaid and Medicare programs to artificially inflate revenue [2]. - Allegations include that GeneDx inflated earnings through the unlawful practice of "code stacking," which allows billing for services that do not meet appropriate standards [2]. Group 2: Insider Trading Allegations - The report also alleges that CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting without participating in open market acquisitions, suggesting insider awareness of potential threats to the business [2]. Group 3: DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [2].